Intellipharmaceutics International is a pharmaceutical company that engages in the research, development and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas. IPCI’s products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders, and many others.  For more information, visit the company’s website at www.intellipharmaceutics.com